L 791456
Latest Information Update: 24 Oct 2021
At a glance
- Originator Merck Frosst
- Class Antirheumatics; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 07 Dec 1999 Phase-I clinical trials in Osteoarthritis in Canada (PO)
- 07 Dec 1999 Phase-I clinical trials in Rheumatoid arthritis in Canada (PO)
- 07 Dec 1999 New profile